Synbiotic supplementation has the potential to decrease the serum concentration of IL-6, TNF-α and hs-CRP, which are risk factors for inflammation-dependent cardiometabolic diseases, such as T2D [189]. The gene discussed is IL6; the disease is type 2 diabetes mellitus.